Latest Cost Management News

Cluey Ltd reported a 50% improvement in EBITDA and its first positive operating cash flow quarter in FY25, driven by cost efficiencies and a return to student growth. The company is now pivoting towards AI-enabled product innovation to fuel sustainable expansion.

Cluey Ltd reported a significantly reduced loss for FY25 alongside an 11% increase in new students and achieved positive operating cash flow in Q4, signaling progress in its path to profitability.

K2 Asset Management posted a 17% revenue increase and returned to profitability in FY25, declaring a fully franked dividend and signalling plans for mergers and acquisitions to accelerate expansion.

K2 Asset Management Holdings Ltd has reported a strong financial year ending June 2025, with revenues up 17% and a return to profitability, alongside a fully franked dividend declaration.

Next Science reports a 42% improvement in adjusted EBITDA loss for 1H FY25 despite a 7% dip in product sales, while shareholders approve a major asset sale to OSARTIS GmbH.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

Frontier Digital Ventures reported a 5% decline in consolidated revenue to A$33.3 million for the first half of 2025, driven by challenges in its Latin American property portal Infocasas. However, the company achieved a robust 71% increase in EBITDA, reflecting improved operational efficiency and strong associate performance in Pakistan.

Orbital Corporation Limited posted a $4.3 million net loss for FY25, reflecting a revenue decline amid production transitions. The company secured a $3 million capital raise to support new UAV engine development and expand its global footprint.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

PointsBet Holdings Limited reported a 6% increase in revenue to $261.4 million for FY2025, alongside a significant reduction in net loss and its first full year of EBITDA profitability. The company’s Australian operations delivered record results while Canadian growth accelerated, setting a positive trajectory for the future.

dusk Group Limited reported solid FY25 results with sales up 8.7% and EBIT rising 22.9%, driven by strong online growth and disciplined cost control. The company signals cautious optimism for FY26 amid product relaunches and store format trials.